177787-25-6

Basic information

• Product Name: Benzoyl chloride, 4-chloro-3-fluoro- (9CI)
• Synonyms: Benzoyl chloride, 4-chloro-3-fluoro- (9CI);4-Chloro-3-fluorobenzoyl chloride 97%;3-Fluoro-4-chlorobenzoyl chloride;4-Chloro-3-fluorobenzoylchloride97%
• CAS NO: 177787-25-6
• Molecular Formula: C₇H₃Cl₂FO
• Molecular Weight: 193.0025232
• Product Categories: ACIDHALIDE
• Mol File: 177787-25-6.mol

Chemical Properties

• Boiling Point: 222℃
• Flash Point: 88℃
• Appearance: /
• Density: 1.462
• CAS DataBase Reference: Benzoyl chloride, 4-chloro-3-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-chloro-3-fluoro- (9CI)(177787-25-6)
• EPA Substance Registry System: Benzoyl chloride, 4-chloro-3-fluoro- (9CI)(177787-25-6)

Safety Data

• HazardClass: CORROSIVE
• Hazardous Substances Data: 177787-25-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzoyl chloride, 4-chloro-3-fluoro(9CI) is used as a key building block for the synthesis of various active pharmaceutical ingredients. It plays a crucial role in the development of anti-inflammatory drugs and antibiotics, contributing to the treatment and management of various health conditions.
Used in Agrochemical Production:
Benzoyl chloride, 4-chloro-3-fluoro(9CI) is utilized as a chemical intermediate in the production of agrochemicals, which are essential for enhancing crop productivity and protecting plants from pests and diseases.
Used in Dye and Fragrance Industries:
Benzoyl chloride, 4-chloro-3-fluoro(9CI) is also employed in the synthesis of dyes and fragrances, contributing to the vibrant colors and appealing scents in various consumer products.
Safety Precautions:
Due to its highly reactive nature, Benzoyl chloride, 4-chloro-3-fluoro(9CI) should be handled with caution to prevent irritation to the eyes, skin, and respiratory system. It is essential to follow proper safety measures during storage and handling to minimize the risk of accidental exposure and potential hazards.

Upstream product

• 403-17-8 4-chloro-3-fluorobenzoic acid 

Downstream Products

• 1027410-69-0 C₁₂H₇Cl₂FN₂O 
• 582323-13-5 4-chloro-N-(2-chloropyrimidin-5-yl)-3-fluorobenzamide 

Relevant articles and documents

Novel hetero-cyclic compound and organic light emitting device comprising the same

The present invention relates to a novel heterocyclic compound, which is capable of increasing efficiency and lifetime in an organic light emitting device, and an organic light emitting device using the same. The novel heterocyclic compound is represented

Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors

We have previously described the identification of indolin-2-one-5-carboxamides as potent PAK4 inhibitors. This study expands the structure-activity relationships on our original series by presenting several modifications in the lead compounds, 2 and 3. A series of novel derivatives was designed, synthesized, and evaluated in biochemical and cellular assay. Most of this series displayed nanomolar biochemical activity and potent antiproliferative activity against A549 and HCT116 cells. The representative compound 10a exhibited excellent enzyme inhibition (PAK4 IC50 = 25 nM) and cellular potency (A549 IC50 = 0.58 μM, HCT116 IC50 = 0.095 μM). An X-ray structure of compound 10a bound to PAK4 was obtained. Crystallographic analysis confirmed predictions from molecular modeling and helped refine SAR results. In addition, Compound 10a displayed focused multi-targeted kinase inhibition, good calculated drug-likeness properties. Further profiling of compound 10a revealed it showed weak inhibitory activity against various isoforms of human cytochrome P450.

N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy

A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC50 of 0.38 μM and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure-activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro- benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure-activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.